Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancerShane W. O’Brien(Millersville University), Andy Fedoriw(South College)BMC CancerAugust 18, 202310.1186/s12885-023-11260-zCited by 32SaveCiteExport RISWatch citationsRelated PapersInvestigating epigenetic therapies and combinations for the treatment of cancers|Unknown|2023|1